The ECRI Institute released a new techIQ brief on key factors to consider when purchasing a linear accelerator (linac) for external beam radiation therapy. The report is a compilation of results from a survey of hundreds of users of linac-based radiosurgery systems; participants were asked to rate the functions and features of the four major linac vendors: Accuray, Brainlab, Elekta and Varian Medical Systems.

Brainlab announced first patient treatments in March on a fully integrated radiation oncology solution that combines its ExacTrac patient positioning with the Elekta Versa HD linear accelerator (LINAC). Working in synergy, these technologies determine positioning and treatment accuracy for cancer patients.

Accuray Inc. announced in April that the InCise Multileaf Collimator (MLC) for the CyberKnife M6 System is available outside the United States in markets where it is approved for sale. The InCise MLC was launched in the U.S. market in February.

Concussion, also known as mild traumatic brain injury (MTBI), is a common medical problem affecting cognitive function and quality of life in some individuals.

In order to sing or speak, around one hundred different muscles in our chest, neck, jaw, tongue, and lips must work together to produce sound. Beckman researchers investigate how all these mechanisms effortlessly work together--and how they change over time.

IBA (Ion Beam Applications S.A.) and Royal Philips announced the signing of an exclusive agreement to enhance access to proton therapy in India. The alliance combines IBA’s strengths in proton therapy and Philips’ expertise in clinical informatics and innovative imaging techniques for therapy planning and guidance.

Hitachi Ltd. announced that Johns Hopkins Medicine has selected Hitachi to provide its proton beam therapy (PBT) system at Sibley Memorial Hospital in Washington, D.C. This collaboration, which includes a 10-year maintenance service, marks the first multi-room PBT application in the nation’s capital. This will be Hitachi’s fifth PBT system in North America.

Augmenix Inc. announced the publication of the 222-patient pivotal study designed to evaluate safety and efficacy of the SpaceOAR System in men undergoing prostate radiotherapy. By creating space between the prostate and rectum, the SpaceOAR System is intended to reduce the radiation dose delivered to the rectum during prostate radiotherapy. The favorable results from the multi-center, randomized, single-blind study led to the April 1, 2015, U.S. Food and Drug Administration (FDA) clearance of the SpaceOAR System.

ScanMed announced the introduction of the non-invasive, wearable ProCure prostate/pelvic magnetic resonance imaging (MRI) coil to aid in diagnosing prostate cancer.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now